olmesartan has been researched along with nevirapine in 4 studies
Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (nevirapine) | Trials (nevirapine) | Recent Studies (post-2010) (nevirapine) |
---|---|---|---|---|---|
841 | 185 | 554 | 3,212 | 509 | 1,108 |
Protein | Taxonomy | olmesartan (IC50) | nevirapine (IC50) |
---|---|---|---|
Chain B, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain B, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain A, Reverse transcriptase/ribonuclease H | Human immunodeficiency virus 1 | 1.165 | |
Prothrombin | Bos taurus (cattle) | 1.15 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 1 BH10 | 1.4504 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 2 (ISOLATE ROD) | 2.05 | |
Gag-Pol polyprotein | HIV-1 M:B_HXB2R | 1.4353 | |
Imidazoleglycerol-phosphate dehydratase | Saccharomyces cerevisiae S288C | 1.7 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 0.181 | |
Cytochrome P450 2C9 | Homo sapiens (human) | 0.181 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.69 | |
Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.7 | |
Microsomal triglyceride transfer protein large subunit | Homo sapiens (human) | 5.75 | |
Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 0.18 | |
Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 2.071 | |
Protease | Human immunodeficiency virus 1 | 0.101 | |
Reverse transcriptase | Human immunodeficiency virus 1 | 3.995 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
4 other study(ies) available for olmesartan and nevirapine
Article | Year |
---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |